The development of a new vaccine as a substitute for Bacillus Calmette–Guerin or to improve its efficacy is one of the many World Health Organization goals to control tuberculosis. Mycobacterial vectors have been used successfully in the development of vaccines against tuberculosis. To enhance the potential utility of Mycobacterium smegmatis as a vaccine, it was transformed with a recombinant plasmid containing the partial sequences of the genes Ag85c, MPT51, and HspX (CMX) from M. tuberculosis. The newly generated recombinant strain mc2-CMX was tested in a murine model of infection. The recombinant vaccine induced specific IgG1 or IgG2a responses to CMX. CD4+ and CD8+ T cells from the lungs and spleen responded ex vivo to CMX, producing IFN-γ, IL17, TNF-α, and IL2. The vaccine thus induced a significant immune response in mice. Mice vaccinated with mc2-CMX and challenged with M. tuberculosis showed better protection than mice immunized with wild-type M. smegmatis or BCG. To increase the safety and immunogenicity of the CMX antigens, we used a recombinant strain of M. smegmatis, IKE (immune killing evasion), to express CMX. The recombinant vaccine IKE-CMX induced a better protective response than mc2-CMX. The data presented here suggest that the expression of CMX antigens improves the immune response and the protection induced in mice when M. smegmatis is used as vaccine against tuberculosis.
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis (Mtb) that is a major public health problem. The vaccine used for TB prevention is Mycobacterium bovis bacillus Calmette-Guérin (BCG), which provides variable efficacy in protecting against pulmonary TB among adults. Consequently, several groups have pursued the development of a new vaccine with a superior protective capacity to that of BCG. Here we constructed a new recombinant BCG (rBCG) vaccine expressing a fusion protein (CMX) composed of immune dominant epitopes from Ag85C, MPT51, and HspX and evaluated its immunogenicity and protection in a murine model of infection. The stability of the vaccine in vivo was maintained for up to 20 days post-vaccination. rBCG-CMX was efficiently phagocytized by peritoneal macrophages and induced nitric oxide (NO) production. Following mouse immunization, this vaccine induced a specific immune response in cells from lungs and spleen to the fusion protein and to each of the component recombinant proteins by themselves. Vaccinated mice presented higher amounts of Th1, Th17, and polyfunctional specific T cells. rBCG-CMX vaccination reduced the extension of lung lesions caused by challenge with Mtb as well as the lung bacterial load. In addition, when this vaccine was used in a prime-boost strategy together with rCMX, the lung bacterial load was lower than the result observed by BCG vaccination. This study describes the creation of a new promising vaccine for TB that we hope will be used in further studies to address its safety before proceeding to clinical trials.
Mycobacterium tuberculosis causes tuberculosis (TB), a disease that killed more than 1.5 million people worldwide in 2014, and the Bacillus Calmette Guérin (BCG) vaccine is the only currently available vaccine against TB. However, it does not protect adults. Th1 and Th17 cells are crucial for TB control, as well as the neutrophils that are directly involved in DC trafficking to the draining lymph nodes and the activation of T lymphocytes during infection. Although several studies have shown the importance of neutrophils during M. tuberculosis infection, none have shown its role in the development of a specific response to a vaccine. The vaccine mc2-CMX was shown to protect mice against M. tuberculosis challenge, mainly due to specific Th1 and Th17 cells. This study evaluated the importance of neutrophils in the generation of the Th1- and Th17-specific responses elicited by this vaccine. The vaccine injection induced a neutrophil rich lesion with a necrotic central area. The IL-17 KO mice did not generate vaccine-specific Th1 cells. The vaccinated IL-22 KO mice exhibited Th1- and Th17-specific responses. Neutrophil depletion during vaccination abrogated the induction of Th1-specific responses and prohibited the bacterial load reduction observed in the vaccinated animals. The results show, for the first time, the role of neutrophils in the generation of specific Th1 and Th17 cells in response to a tuberculosis vaccine.
Although the attenuated Mycobacterium bovis Bacillus Calmette-Guérin
(BCG) vaccine has been used since 1921, tuberculosis (TB) control still proceeds at a
slow pace. The main reason is the variable efficacy of BCG protection against TB
among adults, which ranges from 0-80%. Subsequently, the mc2-CMX vaccine
was developed with promising results. Nonetheless, this recombinant vaccine needs to
be compared to the standard BCG vaccine. The objective of this study was to evaluate
the immune response induced by mc2-CMX and compare it to the response
generated by BCG. BALB/c mice were immunised with both vaccines and challenged
withMycobacterium tuberculosis (Mtb). The immune and inflammatory
responses were evaluated by ELISA, flow cytometry, and histopathology. Mice
vaccinated with mc2-CMX and challenged with Mtb induced an increase in the
IgG1 and IgG2 levels against CMX as well as recalled specific CD4+ T-cells
that produced T-helper 1 cytokines in the lungs and spleen compared with BCG
vaccinated and challenged mice. Both vaccines reduced the lung inflammatory pathology
induced by the Mtb infection. The mc2-CMX vaccine induces a humoral and
cellular response that is superior to BCG and is efficiently recalled after challenge
with Mtb, although both vaccines induced similar inflammatory reductions.
Mycobacterium abscessus complex has been characterized in the last decade as part of a cluster of mycobacteria that evolved from an opportunistic to true human pathogen; however, the factors responsible for pathogenicity are still undefined. It appears that the success of mycobacterial infection is intrinsically related with the capacity of the bacteria to regulate intracellular iron levels, mostly using iron storage proteins. This study evaluated two potential M. abscessus subsp. massiliense genes involved in iron storage. Unlike other opportunist or pathogenic mycobacteria studied, M. abscessus complex has two genes similar to ferritins from M. tuberculosis (Rv3841), and in M. abscessus subsp. massiliense, those genes are annotated as mycma_0076 and mycma_0077. Molecular dynamic analysis of the predicted expressed proteins showed that they have a ferroxidase center. The expressions of mycma_0076 and mycma_0077 genes were modulated by the iron levels in both in vitro cultures as well as infected macrophages. Structural studies using size-exclusion chromatography, circular dichroism spectroscopy and dynamic light scattering showed that r0076 protein has a structure similar to those observed in the ferritin family. The r0076 forms oligomers in solution most likely composed of 24 subunits. Functional studies with recombinant proteins, obtained from heterologous expression of mycma_0076 and mycma_0077 genes in Escherichia coli, showed that both proteins were capable of oxidizing Fe2+ into Fe3+, demonstrating that these proteins have a functional ferroxidase center. In conclusion, two ferritins proteins were shown, for the first time, to be involved in iron storage in M. abscessus subsp. massiliense and their expressions were modulated by the iron levels.
We have thus demonstrated, for the first time, the use of microstructured liposomes as an adjuvant and delivery system for a vaccine formulation against tuberculosis.
This study aimed to evaluate the immunogenicity of a recombinant
Mycobacterium smegmatis vaccine expressing the CMX fusion protein
composed of immunodominant epitopes Ag85C, MPT51 and HspX of Mycobacterium
tuberculosis, which are important mycobacteria virulence factors. A group of
Nelore heifers that were 10 to 12 months of age and negative for the tuberculin skin test
(TST) were immunized with four doses of the recombinant vaccine mc2-CMX
(M. smegmatis-Ag85C-MPT51-HspX) during a period of one
year. Before each immunization, blood was collected to obtain sera for antibody analysis.
Serological analysis demonstrated that mc2-CMX was able to induce a humoral
response with increased levels of specific IgG antibodies against CMX, despite minimum
antibody levels being detected for individual Ag85C, MPT51 or HspX recombinant antigens.
However, there was no significant increase in specific CD4+ IFN-γ-positive T
cells. Lymphadenomegaly was observed in superficial cervical lymph nodes adjacent to the
site of vaccination among mc2-CMX-vaccinated bovines, and the histopathological
analysis demonstrated follicular hyperplasia without inflammatory infiltrate or granuloma
formation. Animals remained negative for the TST until the end of the experiments, showing
no cross-reactivity with the recombinant vaccine and tuberculin proteins. We discuss the
potential of mc2-CMX to induce an immune response in cattle.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.